Oh, another for Pestell besides ctc, going with unmet route first for faster approval using mtnbc, which has expanded into mbc, though that was not his idea. Before that, they had done an animal study in colon cancer and was going the maraviroc path. Those two ideas, ctc and specific area, I gave him credit for. The execution, not so much, unfortunately. But with the safety advantages of leronlimab thus far with those two added strategies, CytoDyn is leading the pack with cancer using Ccr5. All,imo.